Luminice-203 yields its first topline data, but where are all the patients?

The first case reports with the group’s lead Car-T therapy, plus talk of autoimmune diseases and diabetes, prompt a 39% share price surge.

Five years after Affimed switched to NK cell engagers investors will see the fruits of a potentially registrational trial.

The latest failure, in colorectal cancer, follows a recent disappointment in second-line liver.